Dexa Medica
↗Tangerang, Indonesia
Dexa Medica is one of Indonesia's largest pharmaceutical companies, founded in 1969. It operates as a research-based pharmaceutical manufacturer with a strong focus on both generic medicines and innovative, evidence-based natural medicines (OMAI).
The company maintains advanced, integrated research facilities, including the Dexa Development Center (DDC) and Dexa Laboratories of Biomolecular Sciences (DLBS). It is a significant player in the Indonesian healthcare system, supplying medicines for the national health insurance program (JKN) and exporting to over 15 countries across Asia, Africa, and Europe.
CLASSIFICATION
SIZE & FINANCIALS
Employees:5001-10000
Revenue:$500M-$1B
Founded:1969
Ownership:private
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Natural products (Phytopharmaca)
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Dexa Group
Subsidiaries:PT Anugrah Argon Medica (AAM), PT Fonko International Pharmaceuticals
Key Partnerships:Körber Pharma (Digital transformation), PharmEng Technology (Digital transformation)
COMPETITION
Position:Leader
Competitors:Kalbe Farma, Kimia Farma, Sanofi, Novartis
LEADERSHIP
Key Executives:
Ferry A. Soetikno - President Director
Scientific Founders:Rudy Soetikno
LINKS
Website:dexa-medica.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Dexa Medica and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Dexa Medica. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.